Aankondiging • May 13
Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026 Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2026. Aankondiging • Apr 22
Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2026 Results on May 13, 2026 Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2026 results at 1:00 PM, Tokyo Standard Time on May 13, 2026 Aankondiging • Mar 03
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2026 Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the fiscal year ending March 31, 2026. For the year, the company revised revenue of JPY 449,000 million compared to previous guidance of JPY 429,000 million. Core operating profit of JPY 107,000 million compared to previous guidance of JPY 97,000 million. Operating profit of JPY 108,000 million compared to JPY 98,000 million. Net profit attributable to owners of the parent of JPY 102,000 million compared to previous guidance of JPY 92 million. Basic earnings per share of JPY 256.74 per share compared to previous guidance of JPY 231.57 per share. Reasons for the revisions: In the revised forecasts announced today, the Company has changed the full-year foreign exchange assumption (average exchange rate for the period) from JPY 145.0 to JPY 150.0 against 1 USD, as compared with the previous forecast. Revenue has been revised upward by JPY 20.0 billion to JPY 449.0 billion, reflecting higher than expected sales of products such as GEMTESA (therapeutic agent for overactive bladder) in the North America segment, as well as the positive impact of the weaker yen. Core operating profit has been revised upward by JPY 10.0 billion to JPY 107.0 billion. In addition to the increase in gross profit resulting from higher revenue, selling, general and administrative expenses and R&D expenses are now expected to be slightly lower than the previous forecast, excluding the impact of yen depreciation. Driven by the increase in core operating profit, operating profit has been revised upward by JPY 10.0 billion to JPY 108.0 billion and profit attributable to owners of the parent has been revised upward by JPY 10.0 billion to JPY 102.0 billion, compared with the previous forecast. Aankondiging • Feb 13
Sumitomo Pharma Co., Ltd. and Racthera Inc. Announce Scheduled Review in Japan of the Allogeneic Ips Cell-Derived Dopaminergic Neural Proenitor Cells (Amchepry) Sumitomo Pharma Co., Ltd. and RACTHERA Inc. submitted, on August 5, 2025, an application of manufacturing and marketing authorization for allogeneic iPS cell-derived dopaminergic neural progenitor cells for indication of the improvement of motor functions during the off-time period of patients with advanced Parkinson's disease. Sumitomo Pharma and RACTHERA announced that the regenerative medical product AMCHEPRY has been listed as an item for deliberation on the agenda of the upcoming meeting of the Ministry of Health, Labour and Welfare's Pharmaceutical Affairs and Food Sanitation Council, Committee on Regenerative Medicine Products and Biotechnologies, scheduled to be held on February 19, 2026. Aankondiging • Nov 05
Sumitomo Pharma Co., Ltd. to Report Q3, 2026 Results on Jan 30, 2026 Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2026 results at 3:30 PM, Tokyo Standard Time on Jan 30, 2026 Aankondiging • Sep 01
Sumitomo Pharma Co., Ltd. to Report Q2, 2026 Results on Oct 31, 2025 Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2026 results on Oct 31, 2025 Aankondiging • Jul 31
Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506). Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd.
The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025.
Marubeni Global Pharma Co., Ltd. completed the acquisition of 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on July 31, 2025. Aankondiging • Jul 02
Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506). Sawai Group Holdings Co., Ltd. (TSE:4887) agreed to acquire FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on March 28, 2025.
The expected completion of the transaction is June 30, 2025.
Sawai Group Holdings Co., Ltd. (TSE:4887) completed the acquisition of FrontAct Co., Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) on June 30, 2025. Aankondiging • May 16
Sumitomo Pharma Co., Ltd. to Report Q1, 2026 Results on Jul 31, 2025 Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2026 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2025 Aankondiging • Apr 03
Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion. Marubeni Global Pharma Co., Ltd. entered into Share Transfer Agreement to acquire 60% stake in Sumitomo Pharma (China) Co., Ltd. and Sumitomo Pharma Asia Pacific Pte. Ltd. from Sumitomo Pharma Co., Ltd. (TSE:4506) for ¥45.0 billion on April 1, 2025. A cash consideration of ¥45 billion will be paid by Marubeni Global Pharma Co., Ltd.
The transaction is subject to subject to antitrust regulations. The expected completion of the transaction is from July 1, 2025 to September 30, 2025. Aankondiging • Mar 01
Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2025 Results on May 13, 2025 Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2025 results on May 13, 2025 Aankondiging • Feb 01
Sumitomo Pharma Co., Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2025 Sumitomo Pharma Co., Ltd. revised consolidated earnings guidance for the year ending March 31, 2025. For the year, the company expects net sales of JPY 381,000 million, Operating profit of JPY 21,000 million, Net profit attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 earnings per share against net sales of JPY 338,000 million, Operating profit of JPY 0, Net loss attributable to owners of parent is expected to be JPY 16,000 million or JPY 40.27 Loss per share. Reasons for the revisions: The Company has changed assumed exchange rates average exchange rates) for the full-year period from its previous forecasts of JPY 145.0 to JPY 152.0 against 1 USD and JPY 20.0 to JPY 21.0 against RMB 1. Revenue is now expected to be JPY 381.0 billion, up by JPY 43.0 billion from the previous forecast, as sales of ORGOVYX® (therapeutic agent for advanced prostate cancer) and other products remain brisk in the North America segment while sales in China are exceeding plans in he Asia segment, on top of an increase due to the updated forex assumptions. Core operating profit has been revised up by JPY 29.0 billion from the previous forecast to JPY 30.0 billion. This is a result of an increase in gross profit associated with revenue increase, and an expectation that selling, general and administrative expenses and research and development expenses will remain flat due to a decrease in expenses owing to the business structure improvement at the Company, etc., despite an increase due to the updated forex assumptions. Operating profit has been revised to JPY 21.0 billion, up by JPY 21.0 billion from the previous forecast, because of the sheer magnitude of the increase in core operating profit despite the recording of expenses for business structure improvement and otherwise by the Company. Net profit attributable to owners of the parent has been revised to JPY 16.0 billion, reversing the previously forecasted loss of JPY 16.0 billion. Aankondiging • Nov 10
Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025 Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2025 results at 3:30 PM, Tokyo Standard Time on Jan 31, 2025 Aankondiging • Sep 23
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD) Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD) Aankondiging • Aug 07
Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan Sumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Aankondiging • Aug 02
Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024 Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2025 results on Oct 30, 2024 Aankondiging • May 24
Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024 Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2025 results at 3:30 PM, Tokyo Standard Time on Jul 31, 2024 Aankondiging • May 16
Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024 Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024. Aankondiging • Mar 02
Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024 Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2024 results on May 14, 2024 Aankondiging • Dec 15
Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024 Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2024 results on Jan 31, 2024 Aankondiging • Nov 04
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. Aankondiging • Nov 03
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO® Gedeon Richter Plc. together with Sumitomo Pharma America Inc. and Sumitomo Pharma Switzerland, GmbH ('SMPS') announce that the European Commission ('EC') has granted approval of a Type II Variation application for RYEQO® (relugolix 40 mg, estradiol 1.0 mg, and norethisterone acetate 0.5 mg) for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. This decision followed a positive opinion from the Committee for Medicinal Products for Human Use ('CHMP') of the European Medicines Agency ('EMA') on 15 September 2023 and is applicable for all Member States in the European Union. RYEQO® was initially approved by the EMA in July 2021 for the treatment of moderate-to-severe symptoms of uterine fibroids in adult women of reproductive age. Aankondiging • Nov 01
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024 Sumitomo Pharma Co., Ltd. provided dividend guidance for the second quarter and full year of fiscal year ending March 31, 2024. For the period, the company expects to pay dividend of JPY 0.00 against JPY 14.00 a year ago.For the year, the company expects to pay dividend of JPY 0.00 against JPY 7.00 a year ago. Aankondiging • Sep 12
Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia Sumitomo Pharma Co., Ltd. companies, Sumitomo Pharma America Inc. (SMPA) and Sumitomo Pharma Switzerland (SMPS), announced that the Phase 3 UO-901-3005 clinical study of vibegron (GEMTESA®?), a beta-3 adrenergic receptor (b3) agonist, dosed once-daily (75 mg), which is being investigated in men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH), met its co-primary endpoints at Week 12 compared to placebo. The co-primary endpoints include both change from baseline in the average number of micturition (urination) episodes per day and change from baseline in The average number of urgency episodes (the sudden urge to urinate that is difficult to control) per day. U.S., GEMTESA (vibegron) has been indicated for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults since April 2021. GEMTESA works by selectively targeting b3 adrenergic receptors to reduce OAB symptoms through the relaxation of the bladder detrusor muscle to increase capacity. In China, vibegron is currently under investigation in a Phase 3 clinical study for the treatment of OAB. Overactive bladder (OAB) is a clinical condition that occurs when the bladder muscle contracts invol voluntarily. Symptoms may include urinary urgency (the sudden urge to urinating that is difficult to control), urgency incontinence (un intentional loss of urine immediately after an urgent need to urinate), and frequent urination (usually eight or more times in 24 hours). Benign Prostatic Hyperplasia (BPH) is a condition in men in which the prostate gland is enlarged. About 60% of men with BPH are treated for lower urinary tract symptoms (LUTS). LUTS can be divided into storage, voiding, and postmicturition symptoms. Over half of men with BPH report storage symptoms and about a quarter report voiding symptoms. This suggests that many men with a diagnosis of BPH may have overactive bladder. Many men who are treated for symptoms are assumed to have an obstruction in the bladder caused by an enlarged prostate.3,4 About half of all men between ages 51 and 60 have BPH and up to 90% of men over age 80 are living with the condition. Aankondiging • Aug 06
Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023 Sumitomo Pharma Co., Ltd. announced that they will report Q2, 2024 results on Oct 31, 2023 Aankondiging • Aug 02
Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million. Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million on July 30, 2023.Sumitomo Pharma Co., Ltd. (TSE:4506) completed the acquisition of Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac on July 30, 2023. Aankondiging • Jul 31
Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia Sumitomo Pharma Co., Ltd. and Otsuka Pharmaceutical Co., Ltd. announced the topline results from the DIAMOND (the DIAMOND 5 clinical study in Japan and China), generalized anxiety disorder (GAD) and the adjunctive treatment of major depressive disorder (MDD), with additional indications under consideration. Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in May 2019. Ulotaront is the first and only TAAR1 agonist to enter into Phase 3 clinical studies in people living with schizophrenia. It's also the first TAAR1 agonist to entered into Phase 2/3 clinical studies in GAD, and as an adjunctive therapy in MDD. Ulotaront is being jointly developed and commercialized as part of a collaboration between Sumitomo Pharma, its U.S. subsidiary Sumitomo Pharma America Inc. (SMPA), and Otsuka. SMPA discovered ulotaront in collaboration with PsychoGenics based in part on a mechanism-independent approach using the in vivo phenotypic SmartCube®? platform and associated artificial intelligence algorithms. Aankondiging • Jul 11
Sumitomo Pharma Co., Ltd. Announces Executive Changes Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma America Inc. President and Chief Executive Officer, Myrtle Potter, Chief Executive Officer of Biopharma, Adele Gulfo, and Chief Medical Officer, Armin Szegedi, were appointed as Executive Officers of Sumitomo Pharma Co. Ltd. effective July 1, 2023. Aankondiging • Jun 28
Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023 Sumitomo Pharma Co., Ltd. announced that they will report Q1, 2024 results on Jul 31, 2023 Aankondiging • Jun 24
Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd RevolKa Ltd. announced the successful completion of the collaborative drug discovery project with Sumitomo Pharma Co., Ltd. (Hiroshi Nomura, President and CEO) for rare diseases within the contractually agreed time frame. RevolKa designed and identified lead candidates by using its proprietary technology platform called aiProtein®: a robust directed protein evolution technology integrated with artificial intelligence (AI). These lead candidates remarkably exceeded the criteria set in the project. RevolKa delivered them for Sumitomo Pharma’s further research and development for pharmaceutical drug applications. Based on the result, Sumitomo Pharma and RevolKa agreed to declare the milestone achievement. Sumitomo Pharma will receive a ri RevolKa’s proprietary technology, aiProtein® is an AI-assisted directed evolution of proteins. Naturally occurring protein is a linear polymer of 20 amino acids and their derivatives, which folds into a tertial structure through internal complex atomic interactions to show biological function. Proteins have evolved to biologically functional molecules over hundreds of millions of years. The relationship between protein sequence, structure, and function in those highly crafted molecules remains poorly understood to rationally design a protein sequence for a particular function. AI engine is trained with sequence-function relationship data to statistically predict sequences for an evolved protein function. Furthermore, aiProtein® can evolve more than two functions simultaneously. This technology is a powerful and cost-effective tool for the creation of novel and highly-optimized proteins for pharmaceutical and industrial uses. ght of first refusal to an exclusive license of the molecules. RevolKa was entitled to milestone payment. Aankondiging • Jun 23
HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011) HEALIOS K.K. is developing a treatment with Sumitomo Pharma Co. Ltd. utilizing retinal pigment epithelial (RPE) cells derived from allogeneic iPS cells. Company announced that after the completion of the 30-day review by the Pharmaceuticals and Medical Devices Agency (PMDA) regarding the protocol of the phase 1/2 study in patients with RPE tear (hereinafter referred to as "the clinical study"), the preparation of the clinical study has been completed and the study is being initiated. Outline of the clinical study: Test product: HLCR011: iPS cell-derived retinal pigment epithelial (RPE) cells suspension; Development stage: Phase 1/2; Subjects: Patients with retinal pigment epithelium tear; Design for the clinical study (target number cases): Part 1: Unmasked, uncontrolled (one HLA-mismatched subject); Part 2: Unmasked, randomized (treatment/observation groups, 10 subjects/group, total 20 subjects); Primary endpoint: Safety of subretinal administration of HLCR011 in patients with retinal pigment epithelium tear (number and ratio of subjects with observed adverse events); Secondary endpoint (efficacy): Visual function evaluation. The clinical study is a multicenter, unmasked, randomized study. Sumitomo Pharma is now selecting clinical study sites. Subjects will be enrolled immediately after the completion of the preparation, including conclusion of contracts with the clinical study sites. Aankondiging • Jun 10
Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress Sumitomo Pharma Oncology Inc. presented updated preliminary data from the ongoing Phase 1/2 study evaluating TP-3654, an investigational selective oral PIM1 kinase inhibitor, in patients with myelofibrosis (MF) previously treated with or ineligible for JAK inhibitor therapy. Initial preliminary data was presented at American Society of Hematology (ASH) Annual Meeting & Exposition 2022. Updated results were presented in a poster presentation at the European Hematology Association (EHA) 2023 Hybrid Congress, being held June 8-11, 2023 in Frankfurt, Germany as well as virtually on the Congress platform from June 8-11, 2023. Preliminary data of TP-3654 monotherapy in relapsed/refractory myelofibrosis (MF) patients showed spleen volume reduction (SVR), and total symptom score (TSS) improvement.1 Further, TP-3654 may prompt early cytokine changes that may correlate with symptoms response. As of February 9, 2023, 15 patients were enrolled across 5 dose levels from 480mg QD to 720 mg BID. The results showed SVR observed in 7 of 10 evaluable patients treated for = 12 weeks. TSS improvements were observed in 9 of 10 evaluable patients. Broad reductions in cytokines were observed after TP-3654 treatment. At week 12 analysis, patients with higher cytokine reductions correlated with higher TSS improvement. BM fibrosis reduction from grade 3 to 2 was seen in one patient who also achieved spleen and symptoms responses and showed reductions in MF associated cytokines: IL6 (68%), IL12p40 (83%), MMP9 (56%), and EN-RAGE (68%), and is on active treatment for more than 18 months.1 Overall, TP-3654 appears to be well tolerated with no dose limiting toxicity (DLT) observed to date. The most common adverse events are Grade 1 and 2 diarrhea, nausea, and vomiting. Aankondiging • May 16
Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023 Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023. Aankondiging • Feb 03
Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023 Sumitomo Pharma Co., Ltd. announced that they will report fiscal year 2023 results at 1:00 PM, Tokyo Standard Time on May 15, 2023 Aankondiging • Dec 17
Sumitomo Pharma Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023 Sumitomo Pharma Co., Ltd. announced that they will report Q3, 2023 results at 3:30 PM, Tokyo Standard Time on Jan 31, 2023